# BEAM — slm-full-cpu

## Metadata

ticker: BEAM
arm: slm-full-cpu
judge_prompt_version: v2
context_sha256: 698f4684efe21ea639c86b1c114e04c61f765e5a65147a0188816cee03bc3f31
slm_endpoint: slm-cpu
slm_url: http://llamacpp.financial-agent.svc:8080
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-cpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 664, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 144.972, "latency_s_total": 144.972, "parse_failure": 0, "prompt_tokens": 3093, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 468, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 123.392, "latency_s_total": 123.392, "parse_failure": 0, "prompt_tokens": 2340, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 134, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 41.203, "latency_s_total": 41.203, "parse_failure": 0, "prompt_tokens": 665, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 181, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 58.772, "latency_s_total": 58.772, "parse_failure": 0, "prompt_tokens": 659, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 194, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 65.431, "latency_s_total": 65.431, "parse_failure": 0, "prompt_tokens": 540, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 143, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 50.221, "latency_s_total": 50.221, "parse_failure": 0, "prompt_tokens": 744, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 987, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 155.756, "latency_s_total": 155.756, "parse_failure": 0, "prompt_tokens": 1682, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "BEAM",
  "company_name": "Beam Therapeutics Inc.",
  "current_price": 24.5,
  "currency": "USD",
  "market_cap": 2530547712.0,
  "forward_pe": -5.1672826,
  "week_52_high": 38.26,
  "week_52_low": 20.23,
  "revenue": 156035008.0,
  "net_income": -86520000.0,
  "profit_margin": -0.55449003,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-02-24",
    "summary": "Item 1A. Risk Factors. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, in evaluating our company. If any of the events or developments described below were to occur, our business, prospects, operating results and financial condition could suffer materially, and the trading price of our common stock could decline. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. Risks related to our fina"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-04",
    "summary": "Item 1A. Risk Fa ctors. In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in the sections titled sections titled \u201cRisk Factors Summary\u201d and \u201cItem 1A. Risk Factors\u201d in the 2025 Form 10-K, which could materially affect our business, financial condition or future results. The risk factors disclosure in the 2025 Form 10-K is qualified by the information in this Quarterly Report on Form 10-Q. The risks described in the 2025 Form 10\u2013K are not our only risks. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. The risk factors set forth below represent new risk factors o"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided risk factors from the SEC EDGAR filing for ticker BEAM, here are the key takeaways regarding the company's financial position, operational status, and future outlook:

**Financial Performance and Losses**
*   **Significant Operating Losses:** The company has incurred substantial losses since inception, with net losses of $80.0 million (2025), $376.7 million (2024), and $132.5 million (2023). As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **No Profitability:** The company expects to incur significant expenses and increasing operating losses for the foreseeable future and may never achieve or maintain profitability.
*   **Cash Position:** As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities, which is believed to be sufficient to fund operations and capital expenditures for at least the next 12 months.

**Capital Requirements and Funding Risks**
*   **Need for Additional Funding:** The company will require substantial additional capital to continue research and development, expand clinical trials, and potentially commercialize products. There are no committed sources of additional capital other than a credit facility with Sixth Street Lending Partners.
*   **Consequences of Insufficient Funding:** If the company cannot raise capital on acceptable terms or in sufficient amounts, it may be forced to delay, reduce, or eliminate research programs, product development, or commercialization efforts. This could also lead to the termination of license and collaboration agreements.
*   **Dilution and Restrictions:** Raising additional capital through equity or debt may cause dilution to existing stockholders and impose restrictive covenants on the company’s operations.

**Operational Status and Development Stage**
*   **Early-Stage Company:** Founded in 2017, the company has a short operating history. It has not yet completed any pivotal clinical trials, obtained marketing approvals, or manufactured a commercial-scale medicine.
*   **High Risk of Failure:** Many product development programs are in early clinical, preclinical, or research stages, carrying a high risk of failure. The company has not demonstrated the ability to successfully commercialize a product.
*   **Past Restructuring:** In October 2023, the company announced a portfolio repriorization and strategic restructuring, which resulted in the pausing or elimination of certain pipeline programs to reduce operating expenses.

**Future Outlook and Uncertainties**
*   **Unpredictable Timeline:** Due to the numerous risks associated with developing base editing product candidates, the company cannot predict the extent of future losses or when it might become profitable, if ever.
*   **Commercialization Challenges:** Even if product candidates are approved, there is no guarantee of commercial success. The company faces significant challenges in manufacturing, marketing, and distribution, which may need to be established independently or through collaborators.
*   **Evaluation Difficulty:** The company’s short history and the rapidly evolving nature of the base editing and gene editing fields make it difficult to evaluate past performance or predict future viability.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Losses and Need for Capital:** The company has incurred significant operating losses since inception, with net losses of $80.0 million, $376.7 million, and $132.5 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Additional Funding:** Substantial additional funding is required to support continuing operations, including research and development, clinical trials, and potential commercialization. If the company is unable to raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate research and product development programs or future commercialization efforts.
*   **Lack of Commercialization Experience:** The company has not yet demonstrated the ability to successfully complete pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale medicines, or conduct the sales and marketing activities necessary for successful commercialization.
*   **Limited Operating History:** The company has a short history as an operating company, particularly in the rapidly evolving base editing and gene editing fields, which makes it difficult to evaluate its technology, industry, and future performance.
*   **Uncertainty of Product Development:** The process of identifying product candidates and conducting preclinical studies and clinical trials is time-consuming, expensive, and uncertain. The company may never generate the necessary data to obtain marketing approval, and even if products are approved, they may not achieve commercial success.
*   **Dependence on Collaborations and Licenses:** The company’s future capital requirements and ability to maintain license and collaboration agreements depend on various factors, including the success of these agreements and the company's ability to meet payment obligations. Failure to meet these obligations could result in the termination of agreements.
*   **Past Strategic Changes:** The company has previously delayed, reduced, or eliminated research and product development programs to decrease operating expenses, such as through the portfolio reprioritization and strategic restructuring announced in October 2023.

## Pre-written sections (judge input)

### Financial Health

Beam Therapeutics Inc. (BEAM) currently trades at $24.50 with a market capitalization of approximately $2.53 billion. The company reported revenue of $156.04 million, but faces significant profitability challenges with a net loss of $86.52 million, resulting in a negative profit margin of -55.45%. Consequently, the forward P/E ratio is negative at -5.17, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment stage typical of biotechnology firms heavily reliant on future pipeline success rather than current cash flow.

### Recent Developments

Beam Therapeutics Inc. recently filed its 2026 Form 10-K on February 24, 2026, and its 2026 Form 10-Q on August 4, 2026, both of which highlight significant risk factors that could materially impact the company's financial condition and stock price. The filings emphasize that uncertainties and potential adverse events may lead to a decline in trading value, urging investors to carefully consider these risks alongside the company's consolidated financial statements. With a current stock price of $24.50 and a negative profit margin of -55.45%, the company remains in a high-risk phase where operational execution and clinical outcomes are critical for future valuation. Investors should monitor upcoming clinical data and cash burn rates closely, as the disclosed risks suggest potential volatility in the near term.

### SEC Filing Highlights
Beam Therapeutics reported a net loss of $80.0 million for 2025, bringing its accumulated deficit to $1.6 billion, while maintaining a robust cash position of $1.2 billion sufficient to fund operations for at least the next 12 months. The company remains in an early-stage development phase with no commercial products or pivotal trial completions, necessitating substantial additional capital to sustain research and clinical expansion. Management warns that failure to secure future funding on acceptable terms could force delays or terminations of key pipeline programs and collaboration agreements. Consequently, investors face significant risks regarding potential dilution, operational restrictions, and the uncertainty of ever achieving profitability.

### Risk Factors

*   **Persistent Financial Losses and Capital Dependency:** The company has incurred significant operating losses (accumulated deficit of $1.6 billion as of Dec 2025) and expects to continue burning cash, requiring substantial additional funding to sustain operations and R&D; failure to raise capital on attractive terms could force delays or termination of development programs.
*   **High Uncertainty in Product Development and Commercialization:** As a company with a limited operating history and no prior successful commercialization of base editing therapies, BEAM faces significant risks in completing pivotal trials, obtaining regulatory approvals, and manufacturing commercial-scale medicines, with no guarantee of future profitability.
*   **Vulnerability to Strategic Shifts and Collaboration Risks:** The company’s future depends heavily on maintaining collaborative license agreements and managing a volatile pipeline, evidenced by past strategic restructuring that reduced development programs, which could terminate key agreements or limit growth opportunities if obligations are not met.

## Audited (Exec Summary + Outlook)

### Executive Summary
Beam Therapeutics Inc. is a biotechnology firm specializing in base editing therapies, currently trading at $24.50 with a market capitalization of approximately $2.53 billion despite reporting a net loss of $86.52 million. The stock is notable now as the company navigates a high-risk phase with a negative profit margin of -55.45%, relying heavily on future pipeline success rather than current cash flow. The single most important near-term variable shaping the outcome is the successful execution of clinical trials and the ability to secure additional capital to sustain operations beyond the current 12-month runway.

### Outlook
The directional outlook for Beam Therapeutics is cautiously constructive but heavily contingent on binary clinical milestones and capital preservation. Tailwinds include the company’s robust cash position of $1.2 billion, which provides a critical buffer to execute near-term research and clinical expansion without immediate dilution. However, significant headwinds persist, including the accumulated deficit of $1.6 billion and the inherent uncertainty of commercializing base editing therapies without a proven track record. Investors should closely monitor the trend of cash burn rates and the progression of pivotal trial data, as positive clinical outcomes could validate the technology and attract strategic partnerships, while delays or adverse events would likely trigger further capital raises and potential dilution. The thesis strengthens if the company demonstrates clear pathways to regulatory approval and maintains operational discipline, but weakens if funding gaps emerge before commercial viability is achieved.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every quantitative, forward-looking, and specific factual claim in the **Executive Summary** and **Outlook** sections.

---

## EXECUTIVE SUMMARY

---

CLAIM: "currently trading at $24.50"
LABEL: SUPPORTED
REASON: The raw source data explicitly lists `"current_price": 24.5`, matching $24.50.

---

CLAIM: "market capitalization of approximately $2.53 billion"
LABEL: SUPPORTED
REASON: Source data shows `"market_cap": 2530547712.0`; $2,530,547,712 ≈ $2.53 billion.

---

CLAIM: "reporting a net loss of $86.52 million"
LABEL: UNSUPPORTED
REASON: The raw source data shows `"net_income": -86520000.0` (i.e., -$86.52 million), but the SEC Filing Highlights (RAG) explicitly state the 2025 net loss was **$80.0 million**; the $86.52 million figure appears in the stock data field and the Financial Health pre-written section but conflicts with the audited SEC figure of $80.0 million — the two figures are irreconcilable and the SEC-sourced $80.0 million is the more authoritative disclosure for the same period.

---

CLAIM: "negative profit margin of -55.45%"
LABEL: SUPPORTED
REASON: Source data gives `"profit_margin": -0.55449003`; expressed as a percentage this is -55.449%, which rounds to -55.45%, within 0.15 pp of the stated figure. Also explicitly stated in the Financial Health pre-written section.

---

CLAIM: "relying heavily on future pipeline success rather than current cash flow"
LABEL: SUPPORTED
REASON: This is a qualitative restatement directly present in the Financial Health pre-written section ("high-risk investment stage typical of biotechnology firms heavily reliant on future pipeline success rather than current cash flow").

---

CLAIM: "current 12-month runway"
LABEL: SUPPORTED
REASON: The SEC Highlights state the $1.2 billion cash position "is believed to be sufficient to fund operations and capital expenditures for at least the next 12 months," directly supporting the "12-month runway" characterization.

---

## OUTLOOK

---

CLAIM: "robust cash position of $1.2 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state: "As of December 31, 2025, the company held $1.2 billion in cash, cash equivalents, and marketable securities."

---

CLAIM: "provides a critical buffer to execute near-term research and clinical expansion without immediate dilution"
LABEL: INFERENCE
REASON: The source states the $1.2 billion is sufficient for at least 12 months of operations; the "without immediate dilution" qualifier is a direct logical inference from the sufficiency statement, though the source does not use those exact words.

---

CLAIM: "accumulated deficit of $1.6 billion"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state: "As of December 31, 2025, the accumulated deficit stood at $1.6 billion."

---

CLAIM: "uncertainty of commercializing base editing therapies without a proven track record"
LABEL: SUPPORTED
REASON: The SEC Highlights and Risk Factors pre-written section both explicitly state the company has not demonstrated the ability to successfully commercialize a product and has no prior successful commercialization of base editing therapies.

---

CLAIM: "positive clinical outcomes could validate the technology and attract strategic partnerships"
LABEL: UNSUPPORTED
REASON: No source data, news article, SEC filing summary, or pre-written section mentions strategic partnerships as a specific forward-looking outcome contingent on clinical results; this is an introduced claim with no grounding in the provided context.

---

CLAIM: "delays or adverse events would likely trigger further capital raises and potential dilution"
LABEL: SUPPORTED
REASON: The Risk Factors and SEC Highlights explicitly state that failure to secure funding could force delays, and that raising additional capital through equity may cause dilution to existing stockholders — directly supporting this directional claim.

---

CLAIM: "thesis strengthens if the company demonstrates clear pathways to regulatory approval"
LABEL: UNSUPPORTED
REASON: While regulatory approval is discussed as a general risk in the source, no specific "pathway to regulatory approval" milestone, threshold, or timeline is identified in any source section that would ground this as a specific forward-looking claim rather than an introduced editorial assertion.

---

CLAIM: "weakens if funding gaps emerge before commercial viability is achieved"
LABEL: SUPPORTED
REASON: The SEC Highlights and Risk Factors explicitly state that inability to raise capital could force delays or termination of programs, directly supporting the claim that funding gaps before commercial viability would weaken the investment thesis.
